BioSpectrum
the business of Bio & Health Sciences

MedGenome acquires Illumina's NovaSeq X Plus & launches new genome sequencing test

10 July 2023 | News

Launches KaryoSeq to detect genome abnormalities in prenatal and newborn conditions

Bengaluru-based MedGenome becomes the first to offer advanced genomics services using Illumina's NovaSeq X Plus in South Asia. With this, the company anticipates bringing down the reagent cost of Human Whole Genome sequencing to $200 in the near future.

The NovaSeq X Series is Illumina's most powerful sequencing system. With the ability to generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers at shorter turnaround time, this latest sequencer is aimed at making genomics more sustainable and accessible to more people globally.

MedGenome has had a long-standing partnership with Illumina over the last decade expanding its portfolio of sequencing equipment with the latest offerings and becoming leaders in adopting the most up to date sequencing technology. NovaSeq X Plus promises to accelerate a deeper understanding of genetic disorders and can perform a broad range of data-intensive applications, bringing more breakthroughs genetic disease diagnosis and treatment.

In conjunction with this acquisition, MedGenome has launched KaryoSeq (or Karyotype Sequencing), an innovative Whole Genome Sequencing to diagnose prenatal and newborn conditions.

KaryoSeq is a faster and accurate solution which allows for the detection of small chromosomal abnormalities, such as microdeletions or microduplications, that may not be easily identified through microscopic examination alone.